- Record: found
- Abstract: found
- Article: not found
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang
1 ,
Jason Jalil ,
James S Economou ,
Bartosz Chmielowski ,
Richard C Koya ,
Stephen Mok ,
Hooman Sazegar ,
Elizabeth Seja ,
Arturo Villanueva ,
Jesus Gomez-Navarro ,
John A Glaspy ,
Alistair J Cochran ,
Antoni Ribas
Jun 15 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
CTLA4 blocking monoclonal antibodies provide durable clinical benefit in a subset of patients with advanced melanoma mediated by intratumoral lymphocytic infiltrates. A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses.